Compare Stocks: PEN, LNTH, ITGR, and IDXX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IDXX IDEXX Laboratories	$545.08 -1.5%	$559.15	$518.55 ▼ $769.98	$43.60B	1.54	631,781 shs	340,457 shs
ITGR Integer	$125.31 +0.1%	$106.89	$62.00 ▼ $126.14	$4.26B	0.61	1.75 million shs	461,011 shs
LNTH Lantheus	$100.47 -0.3%	$103.80	$49.67 ▼ $111.86	$6.58B	-0.03	2.14 million shs	1.62 million shs
PEN Penumbra	$321.51 -0.5%	$320.62	$221.26 ▼ $362.41	$12.64B	0.7	261,616 shs	476,703 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IDXX IDEXX Laboratories	-1.51%	-0.14%	-4.29%	-3.27%	-14.95%
ITGR Integer	0.00%	+0.01%	+24.91%	+39.94%	+15.87%
LNTH Lantheus	-0.35%	+0.23%	-2.11%	+1.18%	+76.76%
PEN Penumbra	-0.57%	-0.83%	+0.47%	+0.96%	+20.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IDXX IDEXX Laboratories	$545.08 -1.5%	$559.15	$518.55 ▼ $769.98	$43.60B	1.54	631,781 shs	340,457 shs
ITGR Integer	$125.31 +0.1%	$106.89	$62.00 ▼ $126.14	$4.26B	0.61	1.75 million shs	461,011 shs
LNTH Lantheus	$100.47 -0.3%	$103.80	$49.67 ▼ $111.86	$6.58B	-0.03	2.14 million shs	1.62 million shs
PEN Penumbra	$321.51 -0.5%	$320.62	$221.26 ▼ $362.41	$12.64B	0.7	261,616 shs	476,703 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IDXX IDEXX Laboratories	-1.51%	-0.14%	-4.29%	-3.27%	-14.95%
ITGR Integer	0.00%	+0.01%	+24.91%	+39.94%	+15.87%
LNTH Lantheus	-0.35%	+0.23%	-2.11%	+1.18%	+76.76%
PEN Penumbra	-0.57%	-0.83%	+0.47%	+0.96%	+20.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IDXX IDEXX Laboratories	2.60	Moderate Buy	$747.00	37.04% Upside
ITGR Integer	2.07	Hold	$109.86	-12.33% Downside
LNTH Lantheus	2.29	Hold	$108.11	7.61% Upside
PEN Penumbra	2.18	Hold	$367.07	14.17% Upside

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and IDXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	PEN Penumbra	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	ITGR Integer	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/11/2026	IDXX IDEXX Laboratories	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$800.00 ➝ $710.00
8/5/2026	IDXX IDEXX Laboratories	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$650.00 ➝ $670.00
8/5/2026	IDXX IDEXX Laboratories	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$620.00 ➝ $670.00
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
8/4/2026	ITGR Integer	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/4/2026	ITGR Integer	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$84.00 ➝ $127.00
8/3/2026	ITGR Integer	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IDXX IDEXX Laboratories	$4.55B	9.43	$14.86 per share	36.69	$20.47 per share	26.63
ITGR Integer	$1.85B	2.30	$10.37 per share	12.08	$50.56 per share	2.48
LNTH Lantheus	$1.54B	4.25	$6.36 per share	15.79	$20.10 per share	5.00
PEN Penumbra	$1.50B	8.42	$4.28 per share	75.15	$38.86 per share	8.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IDXX IDEXX Laboratories	$1.06B	$14.22	38.33	32.80	2.95	25.03%	71.96%	33.60%	11/2/2026 (Estimated)
ITGR Integer	$102.81M	$3.66	34.24	18.68	2.96	6.97%	12.79%	6.48%	10/22/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.27	18.57	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
PEN Penumbra	$177.69M	$4.07	78.99	51.77	2.00	10.67%	10.50%	8.17%	11/4/2026 (Estimated)

Latest PEN, LNTH, ITGR, and IDXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/4/2026	Q2 2026	IDXX IDEXX Laboratories	$3.94	$4.27	+$0.33	$4.27	$1.20 billion	$1.22 billion
8/3/2026	Q2 2026	ITGR Integer	$1.38	$1.60	+$0.22	$0.69	$451.07 million	$464.11 million
7/30/2026	Q2 2026	PEN Penumbra	$1.16	$0.88	-$0.28	$0.88	$389.64 million	$390.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
ITGR Integer	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PEN Penumbra	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IDXX IDEXX Laboratories	0.19	1.17	0.87
ITGR Integer	0.75	3.73	2.41
LNTH Lantheus	0.43	3.06	2.89
PEN Penumbra	0.01	5.75	3.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IDXX IDEXX Laboratories	87.84%
ITGR Integer	99.29%
LNTH Lantheus	99.06%
PEN Penumbra	88.88%

Insider Ownership

Company	Insider Ownership
IDXX IDEXX Laboratories	0.79%
ITGR Integer	1.10%
LNTH Lantheus	1.70%
PEN Penumbra	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IDXX IDEXX Laboratories	11,000	78.78 million	78.16 million	Optionable
ITGR Integer	11,000	33.99 million	33.62 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
PEN Penumbra	4,700	39.39 million	38.25 million	Optionable

PEN, LNTH, ITGR, and IDXX Headlines

Recent News About These Companies

Jupiter Topco LLC Invests $41.13 Million in Penumbra, Inc. $PEN

2 hours ago | marketbeat.com

Hsbc Holdings PLC Makes New Investment in Penumbra, Inc. $PEN

2 hours ago | marketbeat.com

Man Group plc Invests $25.33 Million in Penumbra, Inc. $PEN

August 27 at 5:36 AM | marketbeat.com

Polar Asset Management Partners Inc. Acquires New Position in Penumbra, Inc. $PEN

August 27 at 5:35 AM | marketbeat.com

Primecap Management Co. CA Takes Position in Penumbra, Inc. $PEN

August 27 at 5:27 AM | marketbeat.com

TFX or PEN: Which Is the Better Value Stock Right Now?

August 26 at 12:41 PM | zacks.com

Penumbra (NYSE:PEN) Rating Increased to Hold at Zacks Research

August 26 at 7:59 AM | marketbeat.com

Sculptor Capital LP Buys New Stake in Penumbra, Inc. $PEN

August 26 at 6:39 AM | marketbeat.com

Kintayl Capital LP Purchases New Position in Penumbra, Inc. $PEN

August 26 at 6:08 AM | marketbeat.com

Commerce Bank Takes $1.17 Million Position in Penumbra, Inc. $PEN

August 26 at 3:52 AM | marketbeat.com

235,328 Shares in Penumbra, Inc. $PEN Purchased by Bank of New York Mellon Corp

August 26 at 3:13 AM | marketbeat.com

Incuvate Files Patent Infringement Lawsuit Against Penumbra

August 25 at 6:44 PM | markets.businessinsider.com

26,200 Shares in Penumbra, Inc. $PEN Acquired by P Schoenfeld Asset Management LP

August 24, 2026 | marketbeat.com

Athos Capital Ltd Acquires New Stake in Penumbra, Inc. $PEN

August 24, 2026 | marketbeat.com

Greenland Capital Management LP Takes Position in Penumbra, Inc. $PEN

August 23, 2026 | marketbeat.com

Trillium Asset Management LLC Acquires New Stake in Penumbra, Inc. $PEN

August 21, 2026 | marketbeat.com

BlackRock Inc. Invests $1.36 Billion in Penumbra, Inc. $PEN

August 21, 2026 | marketbeat.com

Penumbra, Inc. (NYSE:PEN) Receives Consensus Rating of "Hold" from Analysts

August 20, 2026 | americanbankingnews.com

Penumbra, Inc. (NYSE:PEN) Given Average Recommendation of "Hold" by Analysts

August 20, 2026 | marketbeat.com

NINE MASTS CAPITAL Ltd Acquires New Position in Penumbra, Inc. $PEN

August 18, 2026 | marketbeat.com

Citizens Financial Group Inc. RI Invests $9.88 Million in Penumbra, Inc. $PEN

August 18, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PEN, LNTH, ITGR, and IDXX Company Descriptions

IDEXX Laboratories NASDAQ:IDXX

$545.08 -8.36 (-1.51%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$544.84 -0.24 (-0.04%)

As of 07:35 AM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Integer NYSE:ITGR

$125.31 +0.12 (+0.10%)

Closing price 08/27/2026 03:59 PM Eastern

Extended Trading

$125.31 0.00 (0.00%)

As of 08/27/2026 07:30 PM Eastern

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Lantheus NASDAQ:LNTH

$100.47 -0.35 (-0.35%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$100.90 +0.44 (+0.43%)

As of 07:39 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Penumbra NYSE:PEN

$321.51 -1.54 (-0.48%)

Closing price 08/27/2026 03:59 PM Eastern

Extended Trading

$321.31 -0.20 (-0.06%)

As of 07:53 AM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and IDXX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEN, LNTH, ITGR, and IDXX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEN, LNTH, ITGR, and IDXX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEN, LNTH, ITGR, and IDXX Company Descriptions

IDEXX Laboratories NASDAQ:IDXX

Integer NYSE:ITGR

Lantheus NASDAQ:LNTH

Penumbra NYSE:PEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and IDXX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEN, LNTH, ITGR, and IDXX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEN, LNTH, ITGR, and IDXX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEN, LNTH, ITGR, and IDXX Company Descriptions

IDEXX Laboratories NASDAQ:IDXX

Integer NYSE:ITGR

Lantheus NASDAQ:LNTH

Penumbra NYSE:PEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools